Combination Immuno-Oncology Therapies (I-O) have expanded the 1L Therapeutic options available for patients with metastatic melanoma. Clinicians face several obstacles when deciding which I-O agents may provide a benefit in treatment and a chance of survival.
Join the oncology expert to discuss key questions and ongoing results from clinical trials, along with providing expert guidance and recommendations to facilitate integration of recently approved agents into current treatment algorithms.
Key Takeaways/Learning Objectives:
- Interpret recent clinical trials that led to the approval of I-O agents, including 1L combination therapies for the management of metastatic melanoma
- Discuss side effects, indications, and contraindications of 1L I-O therapies used to treat metastatic melanoma
